Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News Alert: FDA approves first TAVR system for aortic regurgitation

News You Need to Know Today
News Alert: FDA approves first TAVR system for aortic regurgitation
Wednesday, March 18, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA approves JenaValve TAVR system for aortic regurgitation

The Trilogy Transcatheter Heart Valve System is the first TAVR device approved by the FDA to treat severe aortic regurgitation. Until now, interventional cardiologists have had to settle for the off-label use of TAVR valves built for treating aortic stenosis. 

READ MORE >
jenavalve TAVR valve for aortic regurgitation acquired by Edwards
Share on Twitter Share on Facebook Share on Linkedin

FDA approves JenaValve TAVR system for aortic regurgitation

Share on Twitter Share on Facebook Share on Linkedin
jenavalve TAVR valve for aortic regurgitation acquired by Edwards
The Trilogy Transcatheter Heart Valve System is the first TAVR device approved by the FDA to treat severe aortic regurgitation. Until now, interventional cardiologists have had to settle for the off-label use of TAVR valves built for treating aortic stenosis. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Breaking News: TCT 2020 to be held virtually
Structural & Congenital Heart Disease | May 2020
Hydroxychloroquine, azithromycin & “potentially lethal” cardiovascular complications | Tele-echocardiography for HF
Selatogrel for heart attack patients | ‘Do-not-resuscitate’ orders for COVID-19 | A tragic loss
Week in Review: New data on cardiologist salaries | COVID-19 updates | Evolocumab & patient outcomes
Updated data on cardiologist salaries | Stroke rates among COVID-19 patients | Evolocumab & patient outcomes
Cath labs join forces to reduce radiation dose | The connection between heart health and cognitive decline

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …341
    • Page 342
    • Page 343
    • Page 344
    • Current page 345
    • Page 346
    • Page 347
    • Page 348
    • Page 349 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup